Navigation Links
Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
Date:8/2/2012

PINE BROOK, N.J., Aug. 2, 2012 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been awarded additional funding from the U.S. Government, valued at $50.2 million, for the advanced development of ETI-204 (Anthim), an investigational agent for the treatment of anthrax infection following a biowarfare attack.  Anthrax is a life-threatening infectious disease caused by the bacterium Bacillus anthracis. Much of the morbidity and mortality of anthrax can be attributed to anthrax toxins. Anthrax remains one of the nation's top biowarfare threats. Inhaled anthrax is often fatal, despite treatment with antibiotics. ETI-204 is an investigational anti-toxin and is a promising candidate for the treatment of inhalational anthrax in humans.

(Logo: http://photos.prnewswire.com/prnh/20090420/NY01624LOGO)

The $50.2 million awarded by the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, will be used to conduct definitive efficacy studies in animals and complete validation of the commercial manufacturing process for ETI-204. This third year of funding is in addition to $57.5 million the company already received under this contract and is part of a five year award totaling up to $143 million. This advanced product development contract is supporting Elusys' efforts to gain U.S. Food and Drug Administration (FDA) licensure, including manufacturing activities, human safety trials and non-clinical effectiveness studies in animals.

"We are pleased that the U.S. Government is continuing to support our efforts to advance ETI-204 through the final stages of our development program, including validation of our commercial manufacturing pro
'/>"/>

SOURCE Elusys Therapeutic, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tom Karagiannis, Ph.D. Awarded Future Fellowship by Australian Research Council (ARC)
2. US Patent awarded for using Metal Peptides to Help Diminish Skin Imperfections
3. Engineer-turned-librarian awarded travel stipend by SPIE Digital Library
4. Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
5. Produce Safety Researchers Awarded by ABC Research Laboratories
6. Cohera Medical Awarded Platform Patent on its Biodegradable Adhesive Technology
7. CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals
8. Chemring Detection Systems Awarded $9M for Biological Detection Systems
9. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
10. Chemring Detection Systems Awarded $500k for Strategic Research and Development
11. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... D.C., USA (PRWEB) May 05, 2015 ... regulations covering a wide range of key photonics technologies ... hampering global competitiveness of U.S. industry. To help the ... webinar on 12 May on the proposed changes ... the commodities covered by International Traffic in Arms Regulations ...
(Date:5/5/2015)... 05, 2015 Research and Markets ... the "Clinical Laboratory, Molecular Diagnostics and Genomic ... 2019 - Global Version" report to their ... the area of molecular diagnostics and pharmacogenics hold ... world market that is moving out of the ...
(Date:5/5/2015)... 2015 CytomX, a biotechnology company developing Probody™ ... Sean McCarthy , D. Phil., chief executive officer, ... New York at 1:15 p.m. ... an overview of CytomX,s Probody pipeline, including the company,s ... About CytomX Therapeutics CytomX Therapeutics develops Probody™ ...
(Date:5/5/2015)... , May 5, 2015   Tocagen Inc. ... David R. Parkinson , M.D., a venture ... appointed to the board of directors of Tocagen. ... experience in oncology clinical development, including leading clinical ... global approvals of the cancer therapeutics Gleevec®, Femara®, ...
Breaking Biology Technology:Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4
... 31 Against the backdrop of a flagging,economy, ... firm in,suburban Atlanta with a future as bright ... FDA approval to market the Embozene(TM),Color-Advanced Microspheres embolization ... a large number of blood vessels in many,locations) ...
... online medical equipment specialists at Medical Machines Online are announcing the release ... HeartStart AED Defibrillator. , ... San Diego, CA (PRWEB) December 31, 2008 ... brand new Philips HeartStart AED Defibrillator. This system is one of many ...
... Its Common Stock to Remain Listed While it ... Palatin Technologies, Inc. (NYSE Alternext US: PTN) today reported ... "Exchange", formerly known as the American Stock Exchange), advising ... conditions of the Exchange,s continued listing standards under Section ...
Cached Biology Technology:First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 2First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 3First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 4Medical Machines Online Announces Release of a Brand New Philips HeartStart AED Defibrillator 2Medical Machines Online Announces Release of a Brand New Philips HeartStart AED Defibrillator 3Palatin Technologies Receives Notification Letter from NYSE Alternext US 2Palatin Technologies Receives Notification Letter from NYSE Alternext US 3
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... irreparable DNA damage normally induce programmed cell death, or ... cells so that transformed cells are able to multiply ... Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered ... degrade a protein that triggers apoptosis in the case ...
... has devastated millions of hectares of rice in southern China ... thousands of tons of the grain at a crucial time ... conference this week in the Philippines. Problems caused by ... one-fifth of a harvest, have intensified across Asia in recent ...
... 3D model of the Blue Tongue virus has been created ... will help biologists devise new ways to combat the virus ... University of Warwick researchers based their model on data ... from Oxford University. The Warwick team used rapid prototyping ...
Cached Biology News:Refusal of suicide order: Why tumor cells become resistant 2Research required urgently to control planthopper pests 2Research required urgently to control planthopper pests 3Engineers create 3-D model to help biologists combat blue tongue virus 2
Rabbit polyclonal to QKI...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... ammonium sulfate are compatible with thermostable enzymes ... and AmpliThem™™ DNA polymerases. You can significantly ... one experiment by adding your own enzyme, ... supplied with the kit. This capability is ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
Biology Products: